Psoriasis Completed Phase 2 Trials for Adalimumab (DB00051)

Also known as: Psoriasis unspecified / Psoriasis, unspecified

IndicationStatusPhase
DBCOND0013339 (Psoriasis)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01483599A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type PsoriasisTreatment
NCT00645814Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque PsoriasisTreatment
NCT00645892Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque PsoriasisTreatment
NCT00645905Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque PsoriasisTreatment
NCT00646191Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque PsoriasisTreatment